Long non-coding RNA FOXP4-AS1 acts as an adverse prognostic factor and regulates proliferation and apoptosis in nasopharyngeal carcinoma
L.-K. Zhong, J. Zhou, X. He, B.-F. He, X.-W. Zhou, J.-L. Zhu, J. Liu, Y.-H. Qiu Department of ENT of The Affiliated Traditional Chinese Medical Hospital of Southwest Medical University, Luzhou City, Sichuan Province, China. xcdh_01@163.com
OBJECTIVE: Nasopharyngeal carcinoma (NPC) is one of the most common malignancies worldwide. In The Cancer Genome Atlas (TCGA) database, the expression level of lncRNA forkhead box P4 antisense RNA 1 (FOXP4-AS1) is higher in NPC samples than in normal samples.
PATIENTS AND METHODS: Quantitative Real-time PCR and Western blotting were performed to detect the expression level of RNA and protein. Luciferase reporter assay ran to test the interactions between FOXP4-AS1 and miR-423-5p and STMN1. Subcellular fractionation assay was used to determine the subcellular localization of FOXP4-AS1. The tumor-promotion functions of FOXP4-AS1 were determined by both in vitro and in vivo assays.
RESULTS: The expression of FOXP4-AS1 was up-regulated in 80 cases with NPC, and these patients with a poor prognosis. Functionally, high expression of FOXP4-AS1 in NPC was connected with promoted cell proliferation and inhibited apoptosis. Moreover, FOXP4-AS1 is located in the cytoplasm of CNE1 (NPC cell lines). Mechanistically, FOXP4-AS1 up-regulated STMN1 on post-transcriptional regulation by means of miR-423-5p.
CONCLUSIONS: Our present study demonstrated that high expression of FOXP4-AS1 in NPC portended poor outcomes. FOXP4-AS1upregulated STMN1 by interacting with miR-423-5p as a competing endogenous RNA (ceRNA) to promote NPC progression.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
L.-K. Zhong, J. Zhou, X. He, B.-F. He, X.-W. Zhou, J.-L. Zhu, J. Liu, Y.-H. Qiu
Long non-coding RNA FOXP4-AS1 acts as an adverse prognostic factor and regulates proliferation and apoptosis in nasopharyngeal carcinoma
Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 15
Pages: 8008-8016
DOI: 10.26355/eurrev_202008_22484